Dr. T. Mike Hsieh, a board-certified urologist and director of the Men's Health Center at UC San Diego Health, specializes in supporting male cancer patients with fertility and sexual health concerns. He collaborates with Moores Cancer Center to help patients preserve their fertility before undergoing cancer treatments and to restore sexual function post-treatment. Dr. Hsieh’s expertise includes managing the sexual side effects of cancer therapies and providing advanced treatments to enhance quality of life for cancer survivors. He also conducts research on fertility preservation and outcomes for male cancer patients, integrating these insights into his clinical practice. Dr. Hsieh completed his urology training at George Washington University and a fellowship at Baylor College of Medicine.
The content within all presentations from the 2024 Testicular Cancer Conference is based on the expert opinion of the presenter including research they have read and/or conducted and is not presented as an endorsement by Testicular Cancer Awareness Foundation, the conference producers, or sponsors.
Background: This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern platinum-based chemotherapy.
Patients and Methods: Eligible TCS were ,55 years of age at diagnosis and treated with first-line platinum-based chemotherapy. Participants underwent physical examinations and completed questionnaires regarding 15 AHOs and health behaviors. Hypogonadism was defined as serum testosterone levels #3.0...
Cure rates for stage 1 testicular cancer are reaching 100%.However, long-term treatment-related side effects pose their own health risks.Regular follow up and monitoring are important for early detection and timely treatment of conditions such astestosterone deficiency and metabolic syndrome.
Testosterone deficiency following testicular cancer
Possible mechanisms for TD following TC
A low testosterone level may be present when TC is diagnosed, or it may follow treatment for the disease...
Dr. Helen Bernie’s presentation delved into the effects of testicular cancer and its treatments on fertility, testosterone levels, and overall well-being. She highlighted the increasing incidence of cancer diagnoses in younger individuals and stressed the importance of addressing fertility preservation for improved quality of life. The talk covered the causes of infertility, available treatment options, and the significance of regular check-ups to manage testosterone levels effectively.
Dr. Ajay Nangia is a professor and vice chair of urology at the University of Kansas Medical Center. Dr. Nangia explains the life cycle of sperm, the relationship between the germ cells of sperm and testicular cancer, fertility as it relates to testicular cancer, sexual health, and much more!
Background:With an increase in the number of cancer survivors each year, male sexual dysfunction becomes an important topic for discussion between patients and providers who treat cancer. The aim of this article is to review the types and mechanisms of sexual dysfunction after cancer therapy and discuss treatment options.
Methods: Contemporary concepts regarding male sexual dysfunction after cancer treatment are reviewed and translated for clinical utility.
Findings:To optimize recovery of erectile capacity after erectile...
Oncosexology is a relatively new term that refers to a multidisciplinary field addressing sexual issues in patients with cancer .1Physicians, nurses, psychologists, and other health care providers can all be involved in the field of oncosexology. An oncosexologist can be any of these practitioners who focus on the sexual function of patients with cancer. This discipline has developed out of a need to adequately address sexual concerns in oncology patients. Cancer remains a significant health burden in the United States, with almost 2 million new cases...
Background: Primary hypogonadism (low testosterone and high luteinizing hormone, LH) is present in approximately 20% of testicular cancer (TC) survivors after orchidectomy with or without chemotherapy.
Objectives: We investigated insulin-like factor 3 (INSL3), a novel marker of Leydig cell function, in TC patients. Materials and Methods: We analyzed: (I) a cross-sectional cohort of TC patients after orchidectomy with or without chemotherapy (1988–1999) at long-term follow-up (median 36 and 35 years of age at follow-up, respectively) and healthy men...
Male infertility due to testicular disorders
Aditi Sharma, Suks Minhas, Waljit S Dhillo, and Channa N Jayasena
Abstract
Context: Male infertility is defined as the inability to conceive following 1 year of regular unprotected intercourse. It is the causative factor in 50% of couples and a leading indication for assisted reproductive techniques (ART). Testicular failure is the most common cause of male infertility, yet the least studied to date.
Evidence Acquisition: The review is an evidence-based summary of male infertility due to testicular failure with a focus...
In this video, the speaker discusses the fundamentals of testicular cancer and emphasizes the importance of optimizing the care for young men with this disease. While testicular cancer is highly curable, it can lead to long-term toxicity due to treatments such as chemotherapy. The speaker suggests novel approaches to minimize toxicity and improve long-term cancer control. They also mention the need to address delays in diagnosis and provide comprehensive care for patients, including fertility preservation and emotional support.
